What topics does this cannabis study cover?

This study covers research on: Addiction, Mental Health.

Umbrella review maps widespread comorbidities across substance use disorders

Q: Where was this research published?

Published in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology on November 10, 2026.

Prevalence and outcomes of co-occurring mental/physical comorbidities and substance use disorders: An atlas umbrella review including 156 systematic reviews with meta-analysis.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology • November 10, 2026 • Review • Moderately Relevant

🤖

AI Summary

This umbrella review brought together 156 systematic reviews with meta-analyses of observational studies to map how substance use disorders (SUDs) co-occur with psychiatric and physical conditions. Across the reviews, high-credibility findings included substantial psychiatric overlap: ADHD was associated with a pooled SUD prevalence of 21.0%, and major depressive disorder had a prevalence of 36.1% among people with opioid use disorder. The review also identified common medical complications, including opioid analgesic use among people with chronic noncancer pain and infectious comorbidities among people who inject drugs.

For cannabis specifically, the abstract reports that schizotypal traits were strongly associated with Cannabis Use Disorder, with no measured heterogeneity across the contributing studies (I² = 0%). Overall, the authors describe SUDs as involving multimorbidity across psychiatric and medical domains and argue for coordinated screening and care. Because this review summarizes observational evidence, it cannot establish that substance use caused the co-occurring conditions or show that any particular care approach is effective; this is an abstract-based summary.

💡 Key Findings

Across the reviewed evidence, psychiatric and physical conditions frequently co-occurred with substance use disorders.

High

90%

ADHD had a pooled SUD prevalence of 21.0%; major depressive disorder prevalence was 36.1% among people with opioid use disorder.

High

90%

The review reported a strong association between schizotypal traits and Cannabis Use Disorder (I² = 0%); this observational finding does not establish causation.

Good

60%

The authors conclude that the breadth of multimorbidity supports cross-domain screening and coordinated care, but the abstract does not establish whether these approaches are effective.

High

90%

📄 Original Abstract

Substance use disorders(SUDs) are intertwined with psychiatric and general medical disorders. Substances of abuse also exert intrinsic toxicities and adverse effects that contribute to extensive somatic multimorbidity, complicating patient prognoses. This umbrella review(UR) systematically aggregated, harmonized, and graded the credibility of meta-analytic evidence concerning SUD comorbidities across psychiatric/somatic dimensions. We searched major electronic databases up to July 2026 for systematic reviews with meta-analyses of observational studies mapping SUD co-occurrences. Extracted data were categorized by ICD-11 diagnostic blocks. Meta-analytic estimates were evaluated using pre-registered quantitative credibility indicators assessing sample size(N), number of studies(k), 95%confidence interval(95%CI) widths, and heterogeneity(I2). The review included 156 systematic reviews with meta-analysis, encompassing 100,441,167 database/registry records across 14,322 study entries, with possible overlap across reviews. High-credibility data showed a strong intra-block psychiatric overlap: Attention-Deficit/Hyperactivity Disorder demonstrated a pooled SUD prevalence of 21.0%(95%CI=17.0-25.0%;k = 31), while Major Depressive Disorder reached a prevalence of 36.1%(95%CI=32.4%-39.7%;k = 161) among patients with Opioid Use Disorder(OUD). Somatic toxicities and iatrogenic pathways were highly prevalent: opioid analgesic use in chronic noncancer pain 27.0%(95%C.I.=23.0-31.0%;N > 3.9 M), and in post-lumbar fusion surgery patients (40.0%;95%C.I.=32.0-49.0%). High prevalences of syndemic infectious comorbidities were observed among populations with injection drug use, with Hepatitis C virus prevalence reaching 61.0%(95%CI=56.0-67.0%) in regional cohorts. Highly specific associations revealed that schizotypal traits strongly correlate with Cannabis Use Disorder(I2=0%). SUDs are multi-systemic disorders characterized by substantial cross-block psychiatric/medical multimorbidity. The breadth and the credibility gradient of multimorbidity argue for routine cross-domain screening and coordinated care, with model effectiveness left to trials.

Paper Type

📚 Review

Publication

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: November 10, 2026
PMID: 43008424
DOI: 10.1016/j.euroneuro.2026.113887

Authors (9)

Michele Fornaro Department of Neurosciences, Section of Psychiatry, Federico II University of Naples, Naples, Italy. Electronic address: dott.fornaro@gmail.com.
Chiara Di Lorenzo Department of Advanced Biomedical Science-Legal Medicine Section, University of Naples "Federico II", Naples, Italy.
Hossam M Ali Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Nicolas A Nunez Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; Department of Psychiatry, University of Utah, Salt Lake, UT, USA.
Giuseppe Di Lorenzo Department of Pharmacy, Federico II University, Naples, Italy.
+4 more authors